<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4087">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292005</url>
  </required_header>
  <id_info>
    <org_study_id>08-006648</org_study_id>
    <nct_id>NCT01292005</nct_id>
  </id_info>
  <brief_title>Pentoxifylline Treatment of Acute Pancreatitis</brief_title>
  <official_title>Pentoxifylline Treatment in Acute Pancreatitis; A Double-Blind Placebo-Controlled Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects (good and bad) of giving a drug called
      pentoxifylline to patients with acute pancreatitis, to see if it can improve blood tests
      associated with inflammation (tissue damage). Pentoxifylline is approved by the US Food and
      Drug Administration (FDA) for treatment of circulation problems, but its use in this study
      is investigational, which means that the FDA has not approved it for the treatment of
      pancreatitis. However, the FDA has allowed the use of pentoxifylline in this research study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be put in one of two groups by chance (as in the flip of a coin). This is done
      so that neither you nor the investigator will know which group you are in.

      You will be put into either the treatment group or the control group.

        -  The treatment group will receive a drug called pentoxifylline

        -  The control group will receive a placebo (matching pill that has no medication in it)
           You will take the pills by mouth starting from the time of admission. You will receive
           a total of 9 doses over the first three days of your hospitalization (72 hours).

      When subject have standard patient care blood draws, additional blood will be taken to do
      the research tests. The additional blood tests will be done every day for up to 5 days,
      after the administration of study drug or till the time of discharge whichever occurs
      earlier. The additional tests will require about 2 teaspoons (10 ml) of blood per day; the
      maximum amount of extra blood taken would be less than 3 tablespoons (40.0 ml). Information
      from your medical record will be gathered while you are hospitalized and after your
      discharge. The study will continue to gather clinical follow up information up to four
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in C-Reactive Protein (CRP)</measure>
    <time_frame>baseline, Day 1, Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>C-reactive protein is produced by the liver. The level of CRP rises when there is inflammation throughout the body. The normal value range for CRP = 1-10 mg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Tumor Necrosis Factor (TNF)-Alpha</measure>
    <time_frame>baseline, Day 1, Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Normal value range for TNF alpha = 0 - 22 pg/ml.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Interleukin (IL) IL-6</measure>
    <time_frame>baseline, Day 1, Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Normal value range for IL-6 = 0 - 5 pg/ml.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Interleukin (IL) IL-8</measure>
    <time_frame>baseline, Day 1, Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Normal value range for IL-8 = 0 - 5 pg/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number Of Subjects With New Onset Organ Failure During Hospitalization</measure>
    <time_frame>1 week or until dismissal date whichever occurs earlier.</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Subjects With New Onset Pancreatic Necrosis During Hospitalization</measure>
    <time_frame>1 week or until dismissal date whichever occurs earlier</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Lengthy Hospital Stays</measure>
    <time_frame>30 days or until dismissal date, whichever occurs earlier</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>&quot;Lengthy&quot; was defined as either greater than 4 days or greater than 10 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>30 days or until dismissal date, whichever occurs earlier</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Unit (ICU) Stay</measure>
    <time_frame>30 days or until dismissal date, whichever occurs earlier</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Needed an Intensive Care Unit Stay</measure>
    <time_frame>30 days, or until dismissal, whichever came first</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <other_name>Trental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Predicted Severe Acute Pancreatitis

          2. Enrollment within 72 hours of diagnosis

          3. Ability to give informed consent

          4. Age &gt;17 years

        Exclusion Criteria:

          1. Moderate or severe congestive heart failure

          2. History of seizure disorder or demyelinating disease

          3. Nursing mothers

          4. Pregnancy

          5. History of prior tuberculosis or risk factors for tuberculosis

          6. Evidence of immunosuppression (malignancy, chronic renal failure, chemotherapy within
             60 days, ongoing steroid treatment*, and HIV)- (*the exception of prednisone use will
             be allowed to participate).

          7. Evidence of chronic pancreatitis from history and examination (however, &quot;acute on
             chronic pancreatitis&quot; diagnosis is allowed)

          8. Evidence of active or pending hemorrhage.

          9. Paralytic ileus with vomiting
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santhi S Vege, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 14, 2016</lastchanged_date>
  <firstreceived_date>October 19, 2010</firstreceived_date>
  <firstreceived_results_date>September 23, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Santhi Swaroop Vege, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pancreatitis</keyword>
  <keyword>pancreatic necrosis</keyword>
  <keyword>severe acute pancreatitis (SAP)</keyword>
  <keyword>Alcoholic pancreatitis</keyword>
  <keyword>gallstone pancreatitis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from the Mayo Clinic in Rochester, Minnesota between 2009 and 2012.</recruitment_details>
      <pre_assignment_details>30 subjects signed informed consent; two subjects were excluded after consent because they were found to be not eligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pentoxifylline</title>
          <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pentoxifylline</title>
          <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="69" lower_limit="34" upper_limit="87"/>
                <measurement group_id="B2" value="58" lower_limit="24" upper_limit="82"/>
                <measurement group_id="B3" value="64" lower_limit="24" upper_limit="87"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30.2" lower_limit="20.6" upper_limit="42.9"/>
                <measurement group_id="B2" value="32.5" lower_limit="16.7" upper_limit="50.1"/>
                <measurement group_id="B3" value="30.3" lower_limit="16.7" upper_limit="50.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in C-Reactive Protein (CRP)</title>
        <description>C-reactive protein is produced by the liver. The level of CRP rises when there is inflammation throughout the body. The normal value range for CRP = 1-10 mg/L.</description>
        <time_frame>baseline, Day 1, Day 3</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in C-Reactive Protein (CRP)</title>
            <description>C-reactive protein is produced by the liver. The level of CRP rises when there is inflammation throughout the body. The normal value range for CRP = 1-10 mg/L.</description>
            <units>mg/L</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Change from baseline to Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48.4" lower_limit="-37.1" upper_limit="207.3"/>
                  <measurement group_id="O2" value="60.6" lower_limit="-71" upper_limit="283.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from baseline to Day 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="62" lower_limit="-157.4" upper_limit="255.3"/>
                  <measurement group_id="O2" value="154" lower_limit="-170" upper_limit="193.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 1. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.62</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 3. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>1.0</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Tumor Necrosis Factor (TNF)-Alpha</title>
        <description>Normal value range for TNF alpha = 0 - 22 pg/ml.</description>
        <time_frame>baseline, Day 1, Day 3</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Tumor Necrosis Factor (TNF)-Alpha</title>
            <description>Normal value range for TNF alpha = 0 - 22 pg/ml.</description>
            <units>pg/ml</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Change from baseline to Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="-1.2" upper_limit="0.52"/>
                  <measurement group_id="O2" value="-0.05" lower_limit="-0.9" upper_limit="49.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from baseline to Day 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.2" lower_limit="-1.0" upper_limit="0.5"/>
                  <measurement group_id="O2" value="-0.3" lower_limit="-3.5" upper_limit="17.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 1. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.72</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 3. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.50</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Interleukin (IL) IL-6</title>
        <description>Normal value range for IL-6 = 0 - 5 pg/ml.</description>
        <time_frame>baseline, Day 1, Day 3</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Interleukin (IL) IL-6</title>
            <description>Normal value range for IL-6 = 0 - 5 pg/ml.</description>
            <units>pg/ml</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Change from baseline to Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.1" lower_limit="-37" upper_limit="25"/>
                  <measurement group_id="O2" value="0.7" lower_limit="-62" upper_limit="152"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from baseline to Day 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-8.6" lower_limit="-61" upper_limit="15.6"/>
                  <measurement group_id="O2" value="-2.9" lower_limit="-213" upper_limit="65.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 1. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.58</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 3. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.80</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Interleukin (IL) IL-8</title>
        <description>Normal value range for IL-8 = 0 - 5 pg/ml.</description>
        <time_frame>baseline, Day 1, Day 3</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in Interleukin (IL) IL-8</title>
            <description>Normal value range for IL-8 = 0 - 5 pg/ml.</description>
            <units>pg/ml</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Change from baseline to Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.0" lower_limit="-7.2" upper_limit="30.8"/>
                  <measurement group_id="O2" value="-1.7" lower_limit="-38.2" upper_limit="49.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from baseline to Day 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.35" lower_limit="-10.3" upper_limit="5.4"/>
                  <measurement group_id="O2" value="-1.9" lower_limit="-43.6" upper_limit="18.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 1. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.90</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 3. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.56</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Of Subjects With New Onset Organ Failure During Hospitalization</title>
        <time_frame>1 week or until dismissal date whichever occurs earlier.</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number Of Subjects With New Onset Organ Failure During Hospitalization</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.09</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Of Subjects With New Onset Pancreatic Necrosis During Hospitalization</title>
        <time_frame>1 week or until dismissal date whichever occurs earlier</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number Of Subjects With New Onset Pancreatic Necrosis During Hospitalization</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.22</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Lengthy Hospital Stays</title>
        <description>&quot;Lengthy&quot; was defined as either greater than 4 days or greater than 10 days.</description>
        <time_frame>30 days or until dismissal date, whichever occurs earlier</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients With Lengthy Hospital Stays</title>
            <description>&quot;Lengthy&quot; was defined as either greater than 4 days or greater than 10 days.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Length of hospitalization &gt;4 days</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Length of hospitalization &gt;10 days</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between arms for length of hospitalization &gt; 4 days. P &lt; 0.05 was considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.04</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison was for length of hospitalization &gt;10 days. P &lt; 0.05 was considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.03</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <time_frame>30 days or until dismissal date, whichever occurs earlier</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Length of Hospital Stay</title>
            <units>days</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3" lower_limit="1" upper_limit="5"/>
                  <measurement group_id="O2" value="5" lower_limit="1" upper_limit="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P &lt; 0.05 was considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.06</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Intensive Care Unit (ICU) Stay</title>
        <time_frame>30 days or until dismissal date, whichever occurs earlier</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Length of Intensive Care Unit (ICU) Stay</title>
            <units>Days</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  <measurement group_id="O2" value="0" lower_limit="0" upper_limit="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P &lt; 0.05 was considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Needed an Intensive Care Unit Stay</title>
        <time_frame>30 days, or until dismissal, whichever came first</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Who Needed an Intensive Care Unit Stay</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P &lt; 0.05 was considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.04</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pentoxifylline</title>
          <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Santhi Swaroop Vege</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-2175</phone>
      <email>vege.santhi@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
